Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628)

Gợi ý tài liệu liên quan:

• Differences between physician and patient preferences for cancer treatments: A systematic review

  13 trang 171 0 0

• Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer

  6 trang 166 0 0

• Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

  7 trang 141 0 0

• 2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France

  9 trang 116 0 0

• Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: A prospective cohort study

  12 trang 92 0 0

• LAP3 contributes to IFN-γ-induced arginine depletion and malignant transformation of bovine mammary epithelial cells

  19 trang 74 0 0

• Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition

  17 trang 62 0 0

• Determinants of late-stage cervical cancer presentation in Ethiopia: A systematic review and meta-analysis

  9 trang 39 0 0

• Anti-proliferative activity of RIHMSQi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases

  12 trang 37 0 0

• Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer

  17 trang 37 0 0